Dosage Forms

Reshaping Dosage Forms

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Frontrunners in Bispecific Antibodies

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Kindeva and BOL Pharma to Develop Inhaled Cannabinoid Products

December 08, 2020

A development agreement will study inhaled formulations of cannabinoid-based drug product for central nervous system diseases.

J&J Initiates COVID-19 Vaccine Approvals in Canada and Europe

December 03, 2020

Janssen announces rolling submissions for its COVID-19 vaccine with Health Canada and EMA.

HPAPI Complexity Prompts New Delivery Mechanisms

December 03, 2020

Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.

BD to Invest $1.2 Billion Over Four Years in Pre-Fillable Syringe Manufacturing Capacity

December 02, 2020

The investment will expand and upgrade manufacturing capacity and technology for pre-fillable syringes and will also includes a new manufacturing facility in Europe.

The COVID-19 Vaccine Blind Spot

December 02, 2020

Transparency and open-dialogue are vital to sway the vaccine-hesitant community.

Prepping Fill/Finish Systems to Ensure Quality Output

December 01, 2020

A holistic approach to validation and quality assurance is essential.

HMA and EMA Release Joint Statement on the Approval of Vaccines

November 24, 2020

HMA and EMA have released a joint statement on the appropriate route for companies to submit marketing authorization applications and the approval processes for vaccines.

Johnson & Johnson Starts Second Global Phase III Clinical Trial of Janssen COVID-19 Vaccine

November 19, 2020

A second global Phase III clinical trial investigating the safety and efficacy of a two-dose regimen of JNJ-78436735 has been initiated by Johnson & Johnson.

Interim Results Show Strong Immune Responses and Better Tolerability in Older Adults for AZD1222

November 19, 2020

Interim results of AZD1222 trial have demonstrated lower reactogenicity in older adults, and strong immune responses across all adult age groups.

EMA Starts Rolling Review of Moderna’s COVID-19 Vaccine Candidate

November 19, 2020

Moderna has reported that EMA's CHMP has started a rolling review of mRNA-1273—Moderna’s COVID-19 vaccine candidate.